Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., developed...
According to the Zhongtong Finance and Economics APP, Chongqing Zhifei Biological Products (300122.SZ) announced that the quadrivalent influenza virus split vaccine (ZFA02 adjuvant) developed by its wholly-owned subsidiary, Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., has obtained the approval notice for clinical trials of preventive vaccines for influenza caused by epidemic strains of influenza virus from the National Medical Products Administration.